Erasca, Inc. (ERAS)
NASDAQ: ERAS · Real-Time Price · USD
16.03
+0.57 (3.69%)
At close: Oct 9, 2026, 4:00 PM EDT
15.55
-0.48 (-2.99%)
After-hours: Oct 9, 2026, 7:30 PM EDT
Erasca Market Cap
Erasca has a market cap or net worth of $5.61 billion as of October 9, 2026. It is the 3,353rd most valuable company in the world and the 1,067th biggest in the United States. Its market cap has increased by 713.37% in one year.
Market Cap
5.61B
Enterprise Value
5.27B
1-Year Change
713.37%
Global Rank
Country Rank
#1,067 United States
Category
ChartMarket Cap Chart
Since the IPO on July 16, 2021, Erasca's market cap has increased from $1.86B to $5.61B, an increase of 201.71%. That is a compound annual growth rate of 23.48%.
| Date | Market Cap | % Change |
|---|---|---|
| Oct 9, 2026 | 5.61B | 431.23% |
| Dec 31, 2025 | 1.06B | 48.72% |
| Dec 31, 2024 | 709.65M | 121.27% |
| Dec 29, 2023 | 320.72M | -50.41% |
| Dec 30, 2022 | 646.73M | -65.76% |
| Dec 31, 2021 | 1.89B | 1.66% |
| Jul 16, 2021 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| CG Oncology | 5.58B |
| Mirum Pharmaceuticals | 5.37B |
| PTC Therapeutics | 5.30B |
| Oruka Therapeutics | 5.28B |
| Cogent Biosciences | 5.25B |
| Scholar Rock Holding | 5.19B |
| CRISPR Therapeutics AG | 5.13B |
| Travere Therapeutics | 5.12B |